| Identification | Back Directory | [Name]
KCN1 | [CAS]
927823-01-6 | [Synonyms]
KCN1
Benzenesulfonamide, N-[(2,2-dimethyl-2H-1-benzopyran-6-yl)methyl]-3,4-dimethoxy-N-phenyl- | [Molecular Formula]
C26H27NO5S | [MOL File]
927823-01-6.mol | [Molecular Weight]
465.56 |
| Hazard Information | Back Directory | [Uses]
KCN1 is a p300/HIF-1α interaction inhibitor. KCN1 inhibits HIF transcriptional activity by binding to the CH1 domain of p300 and preventing the p300/HIF-1α assembly. KCN1 exerts antitumor activities through cell cycle arrest[1][2]. | [IC 50]
p300 | [References]
[1] Shi Q, et al. Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor. ACS Med Chem Lett. 2012 Jun 21;3(8):620-5. DOI:10.1021/ml300042k
[2] Wang W, et al. KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS One. 2012;7(9):e44883. DOI:10.1371/journal.pone.0044883 |
|
|